Berenberg Positive on Concert Pharmaceuticals (CNCE), 'We expect CTP-543 will be commercialized as early as H2 2023'
Tweet Send to a Friend
Berenberg analyst Esther Hong reiterated a Buy rating and $11.00 price target on Concert Pharmaceuticals (NASDAQ: CNCE).The analyst comments "CNCE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
